Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, Safety and Tolerability of ISIS 304801 in Patients With Partial Lipodystrophy
NCT02639286Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Dec 2015
- Primary completion
- Sep 2019
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of volanesorsen in partial lipodystrophy, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Started Dec 2015; status: completed.
02
Drugs
volanesorsen
03
Conditions
partial lipodystrophy
Beyond the preview
Go deeper on NCT02639286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639286.